Prothena Corporation PLC

PRTA remains in a Stage 4 decline with a clear lower-high/lower-low sequence and price trading below its major moving averages. The recent short-covering rally has pushed price into declining 9/21/50 EMAs and verging on resistance at the 200DMA, creating an opportune zone to trim bearish positions. With medium- and long-term trends firmly down and overbought short-term indicators, fading this rally into moving-average resistance aligns with the prevailing downtrend.

• ↑Advancing two partnered programs into Phase III clinical trials
• ↑End-2024 cash $472M vs. projected $168–175M burn in 2025
• ↓Projected 2025 net loss of $244M underscores heavy cash consumption